Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04571372

Enrollment

222

Registered

2020-10-01

Start date

2020-08-14

Completion date

2025-12-13

Last updated

2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Aortic Stenosis or Severe Aortic Regurgitation

Brief summary

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to 99 Years

Healthy volunteers

Inclusion criteria

* Age ≥ 19 yrs * Severe aortic stenosis or severe aortic regurgitation * Agree to consent for self * Can follow-up for the next 2 years

Exclusion criteria

* Pre-existing acute kidney injury * Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy * On ECMO or IABP * Life expectancy \< 12 months * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with adverse clinical outcomes	Immediate post operation	Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

Countries

South Korea

Outcome results